{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:05:13Z","timestamp":1762297513250,"version":"3.37.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00702-009-0323-9","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T09:45:32Z","timestamp":1254822332000},"page":"55-67","source":"Crossref","is-referenced-by-count":15,"title":["The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa"],"prefix":"10.1007","volume":"117","author":[{"given":"Michael John","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrance H.","family":"Andree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Hansard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane C.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Hurtt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Kehne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Pitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Stack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"323_CR1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448\u2013458","journal-title":"Mov Disord"},{"key":"323_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410330515","volume":"33","author":"T Akai","year":"1993","unstructured":"Akai T, Yamaguchi M, Mizuta E, Kuno S (1993) Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33:507\u2013511","journal-title":"Ann Neurol"},{"key":"323_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)09546-1","volume":"273","author":"T Akai","year":"1995","unstructured":"Akai T, Ozawa M, Yamaguchi M, Mizuta E, Kuno S (1995) Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 273:309\u2013314","journal-title":"J Pharmacol Exp Ther"},{"key":"323_CR4","unstructured":"Andree TH, Stack G, Rosenzweig-Lipson S, Coupet J (1999) WAY-135452: a potent novel D2\/D3 partial agonist for the treatment of schizophrenia. In: 38th annual meeting of the American College of Neuropsychopharmacology"},{"key":"323_CR5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1212\/WNL.42.6.1241","volume":"42","author":"F Baronti","year":"1992","unstructured":"Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN (1992) Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 42:1241\u20131243","journal-title":"Neurology"},{"key":"323_CR6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.870080214","volume":"8","author":"D Bravi","year":"1993","unstructured":"Bravi D, Davis TL, Mouradian MM, Chase TN (1993) Treatment of Parkinson\u2019s disease with the partial dopamine agonist EMD 49980. Mov Disord 8:195\u2013197","journal-title":"Mov Disord"},{"key":"323_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-2999(88)90125-2","volume":"148","author":"T Brucke","year":"1988","unstructured":"Brucke T, Bankiewicz K, Harvey-White J, Kopin I (1988) The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur J Pharmacol 148:445\u2013448","journal-title":"Eur J Pharmacol"},{"key":"323_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01249001","volume":"57","author":"A Carlsson","year":"1983","unstructured":"Carlsson A (1983) Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 57:309\u2013315","journal-title":"J Neural Transm"},{"key":"323_CR9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clpt.2003.11.265","volume":"75","author":"MH Vries De","year":"2004","unstructured":"De Vries MH, Hesselink MB, Winsemius AA, Jenner P, Johnston L, Salvage S (2004) SLV 308: plasma levels of effective doses in MPTP-treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans. Clin Pharmacol Ther 75:70","journal-title":"Clin Pharmacol Ther"},{"key":"323_CR10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/syn.20330","volume":"60","author":"JC Glennon","year":"2006","unstructured":"Glennon JC, Van SG, Ronken E, Hesselink MB, Reinders JH, Van Der NM, Long SK, Feenstra RW, McCreary AC (2006) In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 60:599\u2013608","journal-title":"Synapse"},{"key":"323_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2006.08.063","volume":"552","author":"JN Heinrich","year":"2006","unstructured":"Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G\u20acpiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH (2006) Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur J Pharmacol 552:36\u201345","journal-title":"Eur J Pharmacol"},{"key":"323_CR12","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, exander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O\u2019Connell C, Ross T, Richard K, Watts A (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044\u20131053","journal-title":"Arch Neurol"},{"key":"323_CR13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","volume":"204","author":"MJ Jackson","year":"2007","unstructured":"Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P (2007) Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 204:162\u2013170","journal-title":"Exp Neurol"},{"key":"323_CR14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008a) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665\u2013677","journal-title":"Nat Rev Neurosci"},{"key":"323_CR15","doi-asserted-by":"crossref","unstructured":"Jenner P (2008b) Preventing and controlling dyskinesia in Parkinson\u2019s disease\u2014a view of current knowledge and future opportunities. Mov Disord 23(Suppl 3):S585\u2013S598","DOI":"10.1002\/mds.22022"},{"key":"323_CR16","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/156802608785161394","volume":"8","author":"JH Kehne","year":"2008","unstructured":"Kehne JH, Andree TH, Heinrich JN (2008) D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr Top Med Chem 8:1068\u20131088","journal-title":"Curr Top Med Chem"},{"key":"323_CR17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.pharmtox.42.091401.113012","volume":"42","author":"T Kenakin","year":"2002","unstructured":"Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349\u2013379","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"323_CR18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00702-007-0727-3","volume":"114","author":"M Kuoppamaki","year":"2007","unstructured":"Kuoppamaki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P (2007) L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J Neural Transm 114:1147\u20131153","journal-title":"J Neural Transm"},{"key":"323_CR19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-2999(92)90337-4","volume":"212","author":"KW Lange","year":"1992","unstructured":"Lange KW, Loschmann PA, Wachtel H, Horowski R, Jahnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2\u00a0months but not 10\u00a0months after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212:247\u2013252","journal-title":"Eur J Pharmacol"},{"key":"323_CR20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.37.5.863","volume":"37","author":"A Lieberman","year":"1987","unstructured":"Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (1987) Advanced Parkinson\u2019s disease: use of partial dopamine agonist, ciladopa. Neurology 37:863\u2013865","journal-title":"Neurology"},{"key":"323_CR21","first-page":"143","volume":"10","author":"E Martignoni","year":"1995","unstructured":"Martignoni E, Pacchetti C, Aufdembrinke B, Godi L, Albani G, Mancini F, Nappi G (1995) Terguride in stable Parkinson\u2019s disease. Funct Neurol 10:143\u2013146","journal-title":"Funct Neurol"},{"key":"323_CR22","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","volume":"23","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson\u2019s disease. Trends Neurosci 23:S2\u2013S7","journal-title":"Trends Neurosci"},{"key":"323_CR23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.870080408","volume":"8","author":"C Pacchetti","year":"1993","unstructured":"Pacchetti C, Martignoni E, Bruggi P, Godi L, Aufdembrinke B, Miltenburger C, Voet B, Nappi G (1993) Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 8:463\u2013465","journal-title":"Mov Disord"},{"key":"323_CR24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","volume":"10","author":"RK Pearce","year":"1995","unstructured":"Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10:731\u2013740","journal-title":"Mov Disord"},{"key":"323_CR25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"323_CR26","doi-asserted-by":"crossref","unstructured":"Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson\u2019s disease therapy. Ann Neurol 53(Suppl 3):S3\u2013S12","DOI":"10.1002\/ana.10513"},{"key":"323_CR27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00002826-199110000-00010","volume":"14","author":"S Ruggieri","year":"1991","unstructured":"Ruggieri S, Stocchi F, Baronti F, Viselli F, Horowski R, Lucarelli C, Agnoli A (1991) Antagonist effect of terguride in Parkinson\u2019s disease. Clin Neuropharmacol 14:450\u2013456","journal-title":"Clin Neuropharmacol"},{"key":"323_CR28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","volume":"18","author":"LA Smith","year":"2003","unstructured":"Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18:487\u2013495","journal-title":"Mov Disord"},{"key":"323_CR29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1476-5381.1956.tb00006.x","volume":"11","author":"RP Stephenson","year":"1956","unstructured":"Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379\u2013393","journal-title":"Br J Pharmacol Chemother"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0323-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0323-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T15:46:39Z","timestamp":1739375199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0323-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0323-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"type":"print","value":"0300-9564"},{"type":"electronic","value":"1435-1463"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}